InvestorsHub Logo
Followers 62
Posts 1712
Boards Moderated 0
Alias Born 08/08/2005

Re: hayward post# 258688

Tuesday, 03/15/2016 11:34:01 AM

Tuesday, March 15, 2016 11:34:01 AM

Post# of 345891
You must have missed it. "3-9-16/CC STEPHEN WORSLEY (VP/BusinessDev.):
“As Joe provided an update on our collaborations with AstraZeneca and the NCCN, I’d like to provide an update on Peregrine’s other I-O-focused collaboration with the Memorial Sloan Kettering Cancer Center. The goal of this partnership is to evaluate combinations of bavituximab with other checkpoint inhibitors & immune stimulatory agents for the purpose of developing new and increasingly effective anti-cancer treatments. This work is advancing well. To date, we've seen initial signs of activity with new combinations with bavituximab and other treatment modalities, such as checkpoint blockers, T-Cell agonists, * and radiation *. Our plan is to spend the next year investigating these possible combination potentials. We are also renewing the contract for next year as we’ve seen exciting results thus far.”

* AND RADIATION *

MD Anderson, NCCN member institute

Links:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121198516

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121201100


cjgaddy provides volumes of rich information to our board. Thanks a million cj : )

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121189574

The work is well underway with MSK, and is being renewed!!

IMO

sunstar
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News